Theme
GLP-1
The incretin drug class driving the obesity and diabetes supercycle.
GLP-1 receptor agonists are incretin-based therapies that improve glycemic control and drive substantial weight loss. The class underpins a rapidly expanding market spanning diabetes, obesity, and adjacent metabolic conditions.
Companies · 6
Amgen Inc.AMGN
Market cap$203B
Conviction5 / 5
GLP-1Obesity
Read profileEli Lilly and CompanyLLY
Market cap$1.1T
Conviction5 / 5
GLP-1Obesity
Read profileBachem Holding AGBANB
Market cap$6.9B
Conviction4 / 5
GLP-1Metabolic disease
Read profileNovo Nordisk A/SNVO
Market cap$163B
Conviction4 / 5
GLP-1Obesity
Read profileZealand Pharma A/SZEAL
Market cap$3.1B
Conviction3 / 5
ObesityGLP-1
Read profileStructure Therapeutics Inc.GPCR
Market cap$3.5B
Conviction2 / 5
ObesityGLP-1
Read profile